



Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis.

Cécile-Audrey Durel, Elodie Feurer, Jean-Baptiste Pialat, Emilie Berthoux, Roland Chapurlat, Cyrille Confavreux

► To cite this version:

Cécile-Audrey Durel, Elodie Feurer, Jean-Baptiste Pialat, Emilie Berthoux, Roland Chapurlat, et al.. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis.. BMC Neurology, 2013, 13 (1), pp.212. 10.1186/1471-2377-13-212 . inserm-00923470

HAL Id: inserm-00923470

<https://inserm.hal.science/inserm-00923470>

Submitted on 2 Jan 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CASE REPORT

Open Access

Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis

Cécile-Audrey Durel^{2*†}, Elodie Feuer^{1†}, Jean-Baptiste Pialat³, Emilie Berthoux², Roland D Chapurlat¹ and Cyrille B Confavreux¹

Abstract

Background: TNF α blockers have drastically improved rheumatoid arthritis prognosis by preventing joint destruction in DMARD resistant patients. Altering cytokine balance in immune diseases may expose to paradoxical adverse events.

Case presentation: We present the case of a 40-year-old woman, with a confirmed erosive and seropositive RA, successfully treated by TNF α blocker (etanercept) for seven years, and who developed a severe neurosarcoidosis. She had lymphocytic meningitis, bilateral peripheral facial paralysis and anosmia, associated with bilateral hilar lymph nodes, papilloedema, anterior uveitis and elevated serum angiotensin-converting enzyme level. Magnetic resonance imaging showed a bilateral thickening of the Gasser's ganglia walls and enhanced signal of the vestibulocochlear, the facial and the proximal portion of trigeminal nerves.

Conclusion: This case raised the issue of the imputability of etanercept in the development of neurosarcoidosis. Neurological symptoms onset in patients on TNF α blockers should lead to exclude infections, induced lupus but also paradoxical neurosarcoidosis.

Keywords: Neurosarcoidosis, Rheumatoid arthritis, Etanercept, Facial palsy, TNF alpha blockers

Background

Tumor necrosis factor alpha (TNF α) blockers have drastically improved the prognosis of rheumatoid arthritis by preventing joint destruction in DMARD resistant patients. We present the case of a RA patient on etanercept who suddenly developed neurosarcoidosis.

Case presentation

A 40-year-old woman suffered from severe erosive rheumatoid arthritis with positive rheumatoid factor (251 UI/ml [normal <25 UI/ml]) and positive anti-cyclic citrullinated antibodies (64 UA/ml [normal <2.9 UA/mL]). In 2004, etanercept was added to methotrexate to control her disease. In 2008, because of hepatic cytolysis, methotrexate was stopped but etanercept monotherapy maintained the remission. In 2012, she suddenly presented an isolated left peripheral facial palsy. Magnetic resonance

imaging (MRI) showed a contrast-enhancement of the facial nerve. Rapidly, her clinical status worsened with bilateral facial palsy, anosmia, weight loss, dyspnea, eyesight deficiency, eye and mouth dryness. Ophthalmological examination revealed bilateral Bell's phenomenon and left papilloedema with anterior uveitis. Biological analysis revealed elevated serum calcium level (2.56 mmol/L), hyperproteinemia (90 g/L), cytolysis (1.5 N) and cholestasis (4N). Cerebral MRI showed an enhanced signal of cranial nerves on the post enhanced T1-weighted sequences (Figure 1A, B). C-reactive protein was normal. Serologies for Human Immunodeficiency Virus (HIV), hepatitis B, C, syphilis and Lyme were negative. Cerebral fluid analysis showed a lymphocytic meningitis (hyperproteinorachia 0.62g/L and normoglycorrhachia) without oligoclonal band. Polymerase chain reactions of human herpes virus and enterovirus were negative. Chest CT-scan found bilateral hilar and mediastinal lymph nodes. The bronchoalveolar lavage brought a lymphocytic alveolitis (53%) with a high CD4/CD8 lymphocytic ratio of 4.65. Quantiferon[®] assay and mycobacterium culture remained negative. The 18F-fluoride PET-CT supported the diagnosis

* Correspondence: cecile-au@orange.fr

[†]Equal contributors

²Department of Internal Medicine, Hôpital Edouard Herriot, Université de Lyon, Hospices Civils de Lyon, Lyon 69003, France

Full list of author information is available at the end of the article




Figure 1 Axial MRI images of the brain. Post gadolinium enhanced T1 weighted sequence on initial exam shows (A) bilateral focal enhancement of the proximal portion of both trigeminal nerves (arrowheads), (B) bilateral enhancement of the vestibulocochlear and facial nerves, more pronounced on the right side (arrow) and bilateral thickening of the Gasser's ganglia walls (*).

of sarcoidosis showing a fixation of hilar lymph nodes, parotid and submandibular glands without hepatic or other abnormal fixations. Normal serum complement and absence of anti-nuclear antibodies ruled out TNF α induced neurological lupus. Etanercept was stopped and intravenous steroid boluses were initiated (15 mg/kg per day for 3 days) followed by oral prednisolone (1 mg/kg per day). For technical reason, transbronchial lung biopsy was delayed after 1 month of steroid and remained not contributive. Nevertheless, diagnosis of neurosarcoidosis was further supported by an increased level of angiotensin-converting enzyme in serum (77 UI/L [normal value < 68 UI/L]). After 3 months, thanks to a normalization of the liver function, methotrexate (25 mg/week) was added to treat both RA and neurosarcoidosis without another secondary hepatic cytolysis. One year later, she remained on methotrexate and prednisone 20 mg/day: eyesight has completely recovered but not the facial paralysis. Brain MRI showed normalization.

Conclusions

Paradoxical neurosarcoidosis appeared as the RA was in complete remission on etanercept monotherapy for several years. Since we did not obtain histological confirmation, this case is not a definite neurosarcoidosis according to Zajicek's criteria [1]. The delay of one month to perform biopsy while already on steroids may be the reason for non contributive histology. Nevertheless, we eliminated other neurological diseases and the diagnosis was supported by neurological impairment (lymphocytic meningitis, bilateral peripheral facial paralysis, anosmia, eyesight deficiency, papilloedema) associated with anterior uveitis, eye and mouth dryness, weight loss, hypercalcemia and hyperproteinemia. The presence of evidences for systemic sarcoidosis criteria with bilateral hilar lymph nodes, lymphocytic alveolitis, and elevated serum angiotensin-converting enzyme level classified this case as probable [1]. More

recently, chest radiograph and angiotensin-converting enzyme of Zajicek's criteria have been shown to be of insufficient diagnostic value by Marangoni and replaced by chest high resolution computed tomography and bronchoalveolar lavage, with a CD4/CD8 lymphocytic ratio higher than 3.5, of better positive predictive value [2]. According to these revised criteria, our case is still considered as probable [2].

TNF α blockers have already been associated in some cases with "paradoxical" systemic sarcoidosis [3] but only two cases of neurosarcoidosis have been reported and none with etanercept. One occurred in another RA female patient treated by infliximab and methotrexate [4]. The second one refers to a man on adalimumab for an ankylosing spondylitis, who developed seizures [5]. These three cases raise the issue of TNF α blockers imputability on the onset of neurosarcoidosis. Interestingly, some TNF α -blocker-induced sarcoidosis patients did not relapse after rechallenging [6]. However, there are biological arguments to support imputability of TNF α blockers to sarcoidosis onset as a "class effect" rather than a drug specific phenomenon regarding sarcoid-like granulomatous disease occurring during all three anti-TNF therapies. About 40 cases of sarcoid-like granuloma development during anti-TNF therapy have been actually reported in the literature. First, the key pathophysiological feature of sarcoidosis is granuloma. It aims at isolating pathogens and restricting inflammation. As sarcoidosis preferentially involves skin, lungs and eyes, one mechanism relies on the direct exposure to environmental antigens [7]. Thus the induced immunosuppressive condition may favor development of microorganisms involved in sarcoidosis development (*Propionibacterium acnes* or *granulosum*). A second mechanism in sarcoidosis is that granulomas are characterized by local proinflammatory activated CD4 + T lymphocytes with Th1 profile (IFN γ , IL2) stimulating

TNF α production by macrophages. Sarcoidotic patients have simultaneously systemic anergy due to the suppressive abilities of regulatory CD4 + CD25 + FoxP3 T lymphocytes partly triggered by TNF α . Thus TNF α blockade, independently to its anti-inflammatory effect, may be able to stimulate Th17 pathway (IL17, IL23) [8] and to alter T-reg lymphocyte subpopulations [9].

By contrast some studies reported refractory sarcoidosis cases successfully treated by TNF α blockers especially adalimumab and infliximab [10]. Indeed, monoclonal TNF α blockers antibodies are considered to be more effective to block granuloma formation rather than etanercept which partially preserves the mechanisms leading to granuloma formation. This could explain a lack of efficacy of etanercept in granulomatous diseases (e.g. refractory sarcoidosis, crohn's disease).

In addition to paradoxical neurosarcoidosis, other neurological adverse events have been reported with the use of TNF α blockers such as multiple sclerosis [11], polycranial neuritis, chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy [12]. TNF α blockers may trigger the demyelinating process which can evolve independently afterwards [13]. Thus physician should pay a particular attention to patients on TNF α blocker therapy who present any new neurological symptoms.

In conclusion, this case of paradoxical neurosarcoidosis induced by TNF α blockade in a RA patient underlines the risk to destabilize autoimmune profile when using targeted therapies and promote unexpected immune disease.

Consent

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing of interests.

Authors' contributions

EF, CAD, JBP, EB, RDC and CBC diagnosed and treated the patient, contributing equally to writing and revising the manuscript. All authors read and approved the final manuscript.

Author details

¹INSERM UMR 1033 – Université de Lyon, Department of Rheumatology, Hôpital Edouard Herriot, 5, Place d'Arsonval, Hospices Civils de Lyon, Lyon 69003, France. ²Department of Internal Medicine, Hôpital Edouard Herriot, Université de Lyon, Hospices Civils de Lyon, Lyon 69003, France. ³INSERM UMR 1033 – Université de Lyon, Department of Radiology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon 69003, France.

Received: 17 September 2013 Accepted: 23 December 2013
Published: 28 December 2013

References

1. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al: Central nervous system sarcoidosis—diagnosis and management. *QJM Mon J Assoc Physicians* 1999, **92**(2):103–117.
2. Marangoni S, Argentiero V, Tavalato B: Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. *J Neurol* 2006, **253**(4):488–495.
3. Tong D, Manolios N, Howe G, Spencer D: New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. *Intern Med J* 2012, **42**(1):89–94.
4. Sturfelt G, Christensson B, Bynke G, Saxne T: Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. *J Rheumatol* 2007, **34**(11):2313–2314.
5. Mao-Draayer Y, Cash T: Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors. *J Neurol* 2013, **260**(2):651–653.
6. Van der Stoep D, Braunstahl G-J, van Zeven J, Wouters J: Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. *J Rheumatol* 2009, **36**(12):2847–2848.
7. Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. *N Engl J Med* 2007, **357**(21):2153–2165.
8. Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, et al: Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. *Clin Immunol Orlando Fla* 2011, **139**(2):164–176.
9. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med* 2005, **201**(2):233–240.
10. Russell E, Luk F, Manocha S, Ho T, O'Connor C, Hussain H: Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. *Semin Arthritis Rheum* 2013, **43**(1):119–124.
11. Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F: Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. *Rev Neurol* 2007, **163**(12):1232–1235.
12. Jarand J, Zochodne DW, Martin LO, Voll C: Neurological complications of infliximab. *J Rheumatol* 2006, **33**(5):1018–1020.
13. Seror R, Richez C, Sordet C, Rist S, Gossec L, Dires G, et al: Pattern of demyelination occurring during anti-TNF- α therapy: a French national survey. *Rheumatol Oxf Engl* 2013, **52**(5):868–874.

doi:10.1186/1471-2377-13-212

Cite this article as: Durel et al.: Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. *BMC Neurology* 2013 **13**:212.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

